Pro108Ser mutation of SARS-CoV-2 3CL pro reduces the enzyme activity and ameliorates the clinical severity of COVID-19

Recently, an international randomized controlled clinical trial showed that patients with SARS-CoV-2 infection treated orally with the 3-chymotrypsin-like protease (3CL ) inhibitor PF-07321332 within three days of symptom onset showed an 89% lower risk of COVID-19-related hospital admission/ death f...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Scientific reports 2022-01, Vol.12 (1), p.1299
Hauptverfasser:	Abe, Kodai, Kabe, Yasuaki, Uchiyama, Susumu, Iwasaki, Yuka W, Ishizu, Hirotsugu, Uwamino, Yoshifumi, Takenouchi, Toshiki, Uno, Shunsuke, Ishii, Makoto, Maruno, Takahiro, Noda, Masanori, Murata, Mitsuru, Hasegawa, Naoki, Saya, Hideyuki, Kitagawa, Yuko, Fukunaga, Koichi, Amagai, Masayuki, Siomi, Haruhiko, Suematsu, Makoto, Kosaki, Kenjiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Amino Acid Substitution Coronavirus 3C Proteases - genetics Coronavirus 3C Proteases - metabolism COVID-19 - enzymology COVID-19 - genetics Female Humans Male Middle Aged Mutation, Missense Patient Acuity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!